Clinical potential of photodynamic therapy in cardiovascular disorders.
Atherosclerosis and intimal hyperplasia remain obstacles for surgeons to overcome following vascular reconstructions. Even with all of the technical improvements that have occurred in the past several decades, long term patency following intervention is hindered by these inherent adverse developments. Today, the use of light is seen as a potential treatment modality in vascular surgery. Photodynamic therapy (PDT) has been used in the treatment of cancer, and because of its continued success in vascular experimental models it is now being tested in clinical trials for vascular diseases. PDT offers the surgeon many advantages, and it may have unlimited uses in the clinical setting. Is PDT the ultimate treatment modality for the cardiovascular surgeon and will it help to overcome the inherent failures associated with vascular reconstructions? It may be too early to answer these questions, but with the current successes demonstrated by PDT, there is a need for further testing in clinical trials. In the near future, PDT may be used clinically as a treatment modality to inhibit restenosis and intimal hyperplasia following surgical intervention.
Kossodo
S
S
Division of Vascular Surgery, Department of Surgery and Wellman Laboratories of Photomedicine, Massachusetts General Hospital, Boston, Massachusetts 02114, USA.
LaMuraglia
G M
GM
D000818:Animals; D002986:Clinical Trials as Topic; D003324:Coronary Artery Disease / Q000628:therapy*; D023903:Coronary Restenosis / Q000517:prevention & control*; D006801:Humans; D006965:Hyperplasia; D009204:Myocardial Revascularization / Q000009:adverse effects; D010778:Photochemotherapy / Q000009:adverse effects; D017319:Photosensitizing Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D017539:Tunica Intima / Q000473:pathology / Q000528:radiation effects
D017319:Photosensitizing Agents